Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Risk of Hematologic Malignancies in Patients with Acute Myocardial Infarction: A Nationwide Population-Based Cohort Study

Seug Yun Yoon, Sun Young Jeong, Seong Soon Kwon, Mina Kim, Min-Young Lee, Kyoung Ha Kim, Namsu Lee, Jong-Ho Won

Blood (2024) 144 (Supplement 1): 2315.

https://doi.org/10.1182/blood-2024-193311

Published: 2024

Journal Articles

Neutrophil-to-Lymphocyte Ratio Is More Accurate Than Erythropoietin Level for the Polycythemia Vera Diagnosis

Min Jung Kim, Min-Young Lee, Kyoung Ha Kim, Namsu Lee, Jong Ho Won, Seug Yun Yoon

Blood (2022) 140 (Supplement 1): 6868–6869.

https://doi.org/10.1182/blood-2022-165689

Published: 2022

Journal Articles

The Effects of Iron Deficiency on the Gut Microbiota in Young Women

Seug Yun Yoon, Min Jung Kim, Min Young Lee, Kyoung Ha Kim, Namsu Lee, Jong Ho Won

Blood (2022) 140 (Supplement 1): 5348–5349.

https://doi.org/10.1182/blood-2022-162217

Published: 2022

Journal Articles

Risk Stratification for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Simplified Geriatric Assessment: A Prospective, Multicenter, Cohort Study

Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Chang-Hoon Lee, Ga-Young Song, Jae-Yong Kwak, Deok-Hwan Yang

Blood (2022) 140 (Supplement 1): 6719–6720.

https://doi.org/10.1182/blood-2022-159929

Published: 2022

Journal Articles

Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia

Taehyung Kim, Daniela Žácková, Ivana Ježíšková, Anežka Kvetková, Tomáš Jurček, Young Seok Yoo, Hyewon Lee, Kyoung Ha Kim, Myung Hee Chang, Seong Yoon Yi, Jessie J.F. Medeiros, Sagi Abelson, Dennis Kim

Blood (2022) 140 (Supplement 1): 812–814.

https://doi.org/10.1182/blood-2022-162676

Published: 2022

Journal Articles

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Blood (2022) 140 (Supplement 1): 6774–6775.

https://doi.org/10.1182/blood-2022-168228

Published: 2022

Journal Articles

Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 9498–9500.

https://doi.org/10.1182/blood-2022-165716

Published: 2022

Journal Articles

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Blood (2022) 140 (Supplement 1): 6782–6783.

https://doi.org/10.1182/blood-2022-167927

Published: 2022

Journal Articles

Review of End-of-Life Care and Supportive Care during Disease Course in Elderly Patients with Multiple Myeloma

Sunyoung Jeong, Seug Yun Yoon, Min Young Lee, Kyoung Ha Kim, Nam Su Lee, Jong Ho Won

Blood (2021) 138 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2021-150237

Published: 2021

Journal Articles

Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study

Ho-Young Yhim, MD, Cheolwon Suh, Seok Jin Kim, MD PhD, Deok-Hwan Yang, MD PhD, Hyeon-Seok Eom, MD, Kyoung Ha Kim, MD PhD, Yong Park, Jin Seok Kim, MD PhD, Hyo Jung Kim, MD PhD, Dok Hyun Yoon, MD PhD, Won Seog Kim, MD PhD, Jae-Yong Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 4076.

https://doi.org/10.1182/blood-2019-122631

Published: 2019

Journal Articles

No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient

Kyoung Ha Kim, MD PhD, Taehyung Kim, MSc, Jae-Sook Ahn, MD PhD, Zeyad Al-Shaibani, Arjun Law, MD, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Auro Viswabandya, MDDM, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Zhaolei Zhang, PhD, Tamir Biezuner, PhD, Liran I. Shlush, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 4514.

https://doi.org/10.1182/blood-2019-129497

Published: 2019

Journal Articles

High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine

Joon Ho Moon, MD, Hee Jeong Cho, MD, Dong Won Baek, MD, Sang Kyun Sohn, MD PhD, Jae-Sook Ahn, Seo-Yeon Ahn, MD, Seunghyun Choi, PhD, Kyoung Ha Kim, MD PhD, Taehyung Kim, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 4263.

https://doi.org/10.1182/blood-2019-130428

Published: 2019

Journal Articles

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 3317.

https://doi.org/10.1182/blood-2019-125780

Published: 2019

Journal Articles

Bleeding Complications in CAT Patients Treated with LMWH or DOACs

Kyoung Ha Kim, Ho-Young Yhim, MD, Won-Il Choi, Sung-Hyun Kim, MD PhD, Yeung-Chul Mun, MD PhD, Soo-Mee Bang, MD PhD, Doyeun Oh, MD, Ji Hyun Lee, MD PhD, Ji Yun Lee, MD

Blood (2017) 130 (Supplement 1): 4914.

https://doi.org/10.1182/blood.V130.Suppl_1.4914.4914

Published: 2017

Journal Articles

Long-Term Rivaroxaban for the Treatment of Acute Venous Thromboembolism in Patients with Active Cancer in a Prospective Multicenter Trial: KVTE13-01

Ho-Young Yhim, MD, Won-Il Choi, MD, Sung-Hyun Kim, MD PhD, Seung-Hyun Nam, MD, Kyoung Ha Kim, Yeung-Chul Mun, MD PhD, Hun-Gyu Hwang, MD, Doyeun Oh, MD, Keun-Wook Lee, MD, Eun-Kee Song, MD, Yong Shik Kwon, MD, Soo-Mee Bang, MD PhD

Blood (2017) 130 (Supplement 1): 3711.

https://doi.org/10.1182/blood.V130.Suppl_1.3711.3711

Published: 2017

Journal Articles

Clinical Impact of the Immune Reconstitution Status on 100 Day after Allogeneic Stem Cell Transplantation with Fludarabine Based Conditioning

Jin Park, MD, Se Hyung Kim, MD, Sung Hee Lim, MD, Jina Yun, MD, Chan Kyu Kim, MD, Kyoung Ha Kim, Jong-Ho Won, MD, Dae-Sik Hong, MD PhD, Seong Kyu Park, MD

Blood (2017) 130 (Supplement 1): 5486.

https://doi.org/10.1182/blood.V130.Suppl_1.5486.5486

Published: 2017

Journal Articles

Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL)

Kyoung Ha Kim, Lee Jae Hoon, Mark Lee, Kim Hoon-Gu, Young Rok Do, Yong Park, MD PhD, Sung Yong Oh, MD, Ho-Jin Shin, MD PhD, Won Seog Kim, Sung-Kyu Park, MD, Jong-Ho Won, Jee Hyun Kong, Moo-Rim Park, MD, Je-Jung Lee, Jae-Yong Kwak, Hye Jin Kang, MD PhD, Yeung-Chul Mun

Blood (2016) 128 (22): 3466.

https://doi.org/10.1182/blood.V128.22.3466.3466

Published: 2016

Journal Articles

Prospective, Non-Randomized, Open-Label, Single-Arm, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin 10% Formulation in Patients with Immune Thrombocytopenia (ITP)

Soo-Mee Bang, Yeung-Chul Mun, Ho-Jin Shin, MD PhD, Chul Won Jung, Sung Hwa Bae, Sang Kyun Sohn, Kyoung Ha Kim, Hawk Kim, Ho-Young Yhim, MD PhD, Junshik Hong, Hye Joo Kim, Jae-hoon Lee, Doyeun Oh

Blood (2016) 128 (22): 4938.

https://doi.org/10.1182/blood.V128.22.4938.4938

Published: 2016

Journal Articles

Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome

Hawk Kim, MD PhD, Je-Hwan Lee, MD PhD, Won-Sik Lee, MD, Inho Kim, Joon Ho Moon, MD, PhD, Chul Won Choi, MD PhD, Ho Sup Lee, MD PhD, Jinny Park, Ho-Jin Shin, Kyoung Ha Kim, MD, Su-Hee Cho, MD PhD, Sung-Yong Kim, MD, Yoo-Jin Kim

Blood (2015) 126 (23): 1687.

https://doi.org/10.1182/blood.V126.23.1687.1687

Published: 2015

Journal Articles

Survey of Qol (quality of life) on Patients Receiving Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Korean CML Working Party Group

Kyoung Ha Kim, Dae-Young Kim, MD PhD, Sung-Hyun Kim, Yeo-Kyeoung Kim, Inho Kim, Hee-Jin Kim, MD PhD, Sang Kyun Sohn, MD PhD, Jeon-Ok Lee, June-Won Cheong, MD, PhD, Chul Won Jung, MD PhD, Young-Uk Cho, MD PhD

Blood (2015) 126 (23): 5166.

https://doi.org/10.1182/blood.V126.23.5166.5166

Published: 2015

NARROW

Risk of Hematologic Malignancies in Patients with Acute Myocardial Infarction: A Nationwide Population-Based Cohort Study

Neutrophil-to-Lymphocyte Ratio Is More Accurate Than Erythropoietin Level for the Polycythemia Vera Diagnosis

The Effects of Iron Deficiency on the Gut Microbiota in Young Women

Risk Stratification for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Simplified Geriatric Assessment: A Prospective, Multicenter, Cohort Study

Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Review of End-of-Life Care and Supportive Care during Disease Course in Elderly Patients with Multiple Myeloma

Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study

No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient

High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Bleeding Complications in CAT Patients Treated with LMWH or DOACs

Long-Term Rivaroxaban for the Treatment of Acute Venous Thromboembolism in Patients with Active Cancer in a Prospective Multicenter Trial: KVTE13-01

Clinical Impact of the Immune Reconstitution Status on 100 Day after Allogeneic Stem Cell Transplantation with Fludarabine Based Conditioning

Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL)

Prospective, Non-Randomized, Open-Label, Single-Arm, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin 10% Formulation in Patients with Immune Thrombocytopenia (ITP)

Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome

Survey of Qol (quality of life) on Patients Receiving Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Korean CML Working Party Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only